**Core Concept**
The PCSK9 inhibitors are a class of drugs that target the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, which plays a crucial role in regulating cholesterol levels in the blood by controlling the recycling of low-density lipoprotein receptors (LDLR) on the surface of liver cells. By inhibiting PCSK9, these drugs increase the number of LDLR on the liver surface, leading to increased clearance of LDL cholesterol from the bloodstream.

**Why the Correct Answer is Right**
Evolocumab is a human monoclonal antibody that specifically binds to PCSK9, preventing it from interacting with LDLR on the liver surface. This binding inhibits the degradation of LDLR, leading to an increase in the number of functional LDLR on the liver surface, which in turn increases the clearance of LDL cholesterol from the bloodstream. As a result, evolocumab reduces the levels of LDL cholesterol and apolipoprotein B in patients with hypercholesterolemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Alirocumab is another PCSK9 inhibitor, but it is not the correct answer as the question asks for a "new drug".
**Option B:** Prasugrel is an antiplatelet agent that inhibits the P2Y12 receptor, not PCSK9.
**Option C:** Rosuvastatin is a statin that inhibits HMG-CoA reductase, not PCSK9.
**Option D:** Atorvastatin is also a statin that inhibits HMG-CoA reductase, not PCSK9.

**Clinical Pearl / High-Yield Fact**
PCSK9 inhibitors like evolocumab are particularly useful in patients with familial hypercholesterolemia, who have a genetic deficiency of LDLR and are resistant to statin therapy.

**Correct Answer:** A. Evolocumab.